Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

Author:

Cavender Matthew A.1ORCID,Harrington Robert A.2,Stone Gregg W.3ORCID,Steg Ph. Gabriel45ORCID,Gibson C. Michael6,Hamm Christian W.7,Price Matthew J.8ORCID,Lopes Renato D.9ORCID,Leonardi Sergio10ORCID,Deliargyris Efthymios N.11ORCID,Prats Jayne12ORCID,Mahaffey Kenneth W.2,White Harvey D.13ORCID,Bhatt Deepak L.14ORCID,Harrington Robert A.,Huber Kurt,Lima Valter C.,Jorgova-Makedonska Julia B.,Widimský Petr,Kobulia Bondo,Radke Peter W.,Bramucci Ezio,Witkowski Adam,Shlyakhto Evgeny,Van de Werf Frans,Faxon David P.,Ohman E. Magnus,Verheugt Freek W.A.,Weaver W. Douglas,Tijssen Jan G.P.,Wilson Matthew,Mangum Stacey,Melloni Chiara,Brennan Matthew J.,Tricoci Pierluigi,Harrison Robert,Barros Pedro,Armaganijan Luciana,Anderson Monique,Bagai Akshay,Généreux Philippe,Brener Sorin J.,LaSalle Laura,Benzer Werner,Delle-Karth Georg,Huber Kurt,Leisch Franz,Abdalla Saad Jamil,Abizaid Alexandre,Augusto Formiga Areas Carlos,Ribeiro Expedito E.,Rossi Dos Santos Fabio,Tadeu Tumelero Rogerio,Vieira Botelho Roberto,Atzev Borislav,Boichev Boicho,Grigorov Georgi,Penkov Nikolay,Petrov Ivo,Zehirov Boris,Cervinka Pavel,Coufal Zdenek,Hajek Petr,Horak David,Kala Petr,Kmonicek Petr,Kocka Viktor,Mrozek Jan,Simek Stanislav,Sitar Jan,Stasek Josef,Tousek Frantisek,Chapidze Gulnara,Emukhvari Nodar,Khabeishvili George,Mamatsashvili Merab,Shaburishvili Tamaz,Behrens Steffen,Darius Harald,Dissmann Martin,Fichtlscherer Stephan,Franz Wolfgang,Geisler Tobias,Genth-Zotz Sabine,Goldmann Britta,Heuer Hubertus,Hoffmann Stefan,Mugge Andreas,Poerner Tudor,Radke Peter,Richardt Gert,Stellbrink Christoph,Werner Nikos,Bramucci Ezio,De Servi Stefano,Galasso Gennaro,Menozzi Alberto,Musumeci Giuseppe,Picchi Andrea,Presbitero Patrizia,Devlin Gerard,Sasse Alexander,Scott Douglas,Stewart Ralph,Andrzej Szyszka,Dubaniewicz Witold,Gasior Zbigniew,Kasprzak Jaroslaw,Kleinrok Andrzej,Kornacewicz-Jach Zdzislawa,Rynkiewicz Andrzej,Sosnowski Cezary,Targonski Radoslaw,Trebacz Jaroslaw,Witkowski Adam,Zinka Elzbieta,Barbarash Olga,Dovgalevsky Yakov,Gordeev Ivan,Kalinina Svetlana,Kosmachova Elena,Markov Valentin,Pavlov Prokhor,Shalaev Sergey,Shogenov Zaur,Sukmanova Irina,Vasilieva Elena,Yakovlev Alexey,Boonbaichaiyapruck Sarana,Chamnarnphol Noppadol,Kaewsuwanna Pinij,Kuanprasert Srun,Piyayotai Dilok,Amine Maged,Angiolillo Dominick,Arif Imran,Blankenship James,Brilakis Emmanouil,Chan Michael,Cinderella Joseph,Davis Brent,Devireddy Chandanreddy,Dorogy Mark,Douglas John,Ferrier Norman,Fisher Daniel,Foster Robert,French William,Galla John,Gimple Lawrence,Gogia Harinder,Gogo Prospero,Gollapudi Raghava,Gruberg Luis,Hermiller James,Heuser Richard,Iwaoka Robert,Jafar Zubair,Kimmelstiel Carey,Kinlay Scott,Leggett James,Leimgruber Pierre,Letts Dustin,Lipsitt Michael,Low Reginald,Martinez-Arraras Joaquin,Mayhew Marc,McLaurin Brent,McWhirter Paul,Mirza Ayoub,Negus Brian,Nygaard Thomas,O’Riordan William,Paulus Richard,Petersen John,Picon Hector,Picone Mark,Rivera Ernesto,Rizik David,Rizik David,Rodriguez Arsenio,Saucedo Jorge,Scott J. Christopher,Sethi Virender,Shroff Adhir,Siegel Craig,Spriggs Douglas,Steinberg Daniel,Stillabower Michael,Stuckey Thomas,Suarez Jose,Tauth Jeffrey,Temizer Dogan,Vidovich Mladen,Voeltz Michele,Waltman Jonathan,Wilensky Michael

Affiliation:

1. University of North Carolina, Chapel Hill (M.A.C.).

2. Stanford University, Palo Alto, CA (R.A.H., K.W.M.).

3. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York City, NY (G.W.S.).

4. Université Paris-Diderot, Sorbonne Paris Cité, INSERM U-1148, DHU FIRE, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, France (P.G.S.).

5. Institute of Cardiovascular Medicine and Science, National Lung and Heart Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.).

6. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.M.G.).

7. Kerckhoff Clinic and Thoraxcenter, Bad Nauheim, Germany (C.W.H.).

8. Scripps Clinic, La Jolla, CA (M.J.P.).

9. Duke Clinical Research Institute, Durham, NC (R.D.L.).

10. University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (S.L.).

11. Science and Strategy Consulting Group, Basking Ridge, NJ (E.N.D.).

12. Elysis LLC, Carlisle, MA (J.P.).

13. University of Auckland, Auckland City Hospital, Auckland, New Zealand (H.D.W.).

14. Brigham and Women’s Hospital, Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).

Abstract

Background: Thrombotic events are reduced with cangrelor, an intravenous P2Y 12 inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). Methods: CHAMPION PHOENIX was a double-blind, placebo-controlled trial that randomized patients undergoing percutaneous coronary intervention to cangrelor or clopidogrel. For this analysis, we evaluated the efficacy of cangrelor in the first 2 hours postrandomization with regards to the primary end point (death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis). Sensitivity analyses were performed evaluating a secondary, post hoc end point (death, Society of Coronary Angiography and Intervention myocardial infarction, ischemia-driven revascularization, or Academic Research Consortium definite stent thrombosis). Results: The majority of events (63%) that occurred in the trial occurred within 2 hours of randomization. The most common early event was myocardial infarction; next were stent thrombosis, ischemia driven revascularization, and death. In the first 2 hours after randomization, cangrelor significantly decreased the primary composite end point compared with clopidogrel (4.1% versus 5.4%; hazard ratio, 0.76 [95% CI, 0.64–0.90], P =0.002). Similar findings were seen for the composite end point of death, Society of Coronary Angiography and Intervention myocardial infarction, ischemia-driven revascularization, or Academic Research Consortium stent thrombosis at 2 hours (0.9% versus 1.6%; hazard ratio, 0.57 [95% CI, 0.40–0.80], P =0.001). Between 2 and 48 hours, there was no difference in the primary composite end point (0.6% versus 0.5%; odds ratio, 1.17 [95% CI, 0.71–1.93]; P =0.53). Early (≤2 hours of randomization) GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) moderate or severe bleeding events were infrequent, and there was no significant difference with cangrelor compared with clopidogrel (0.2% [n=10] versus 0.1% [n=4]; adjusted odds ratio, 1.41 [95% CI, 0.37–5.40]; P =0.62). Conclusions: The reductions in ischemic events and overall efficacy seen with cangrelor in CHAMPION PHOENIX occurred early and during the period of time in which patients were being actively treated with cangrelor. These findings provide evidence that supports the importance of potent platelet inhibition during percutaneous coronary intervention. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01156571.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3